There is mounting interest for researchers to start conducting studies with humans as soon as possible to find a vaccine and therapeutic treatments that are safe and effective, write Hastings Center research scholars Karen Maschke and Michael Gusmano, who also is an associate professor at Rutgers School of Public Health. The authors are “not eager to see Covid-19 interventions join the list of others that entered the clinic on the basis of limited or contested evidence of effectiveness and then harmed patients or proved to be ineffective. ” They suggest that effective strategies to minimize this risk require commitment from scientists, physicians, policymakers, patients, and the general public. To read the full article.
Recent Posts
- Join Clinical Trials Day at Rutgers on 5/20
- NJ ACTS Success Story – The Kiosk Project
- Doctors Explain How to Tell the Difference Between Cold, Flu, and COVID-19 Symptoms.
- NJACTS Community Engagement Core COVID-19 Resources
- Join NJ ACTS Biostatistics, Epidemiology, Research Design (BERD)on 5/28 at 12pm
Categories
- Community (2,489)
- Covid (1,001)
- CTO Events (6)
- News (3,161)
- Pilots (21)